ArticleEndocrinology, diabetes & metabolism case reports2025
A subtle initial clinical presentation of a TSH-secreting PitNET.
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: Thyroid stimulating hormone (TSH)-secreting PitNETs, also called TSHomas, are rare benign pituitary tumors with an incidence of 1.0 per million population. They are generally diagnosed in the context of central hyperthyroidism and/or mass-effect central symptomatology (e.g. headache, bitemporal hemianopsia, and panhypopituitarism). Although TSHomas are more often macroadenomas than microadenomas at the time of diagnosis, diagnosing TSHomas may be challenging because laboratory findings and clinical presentation are not always obvious. The treatment of choice is the surgical resection of the adenoma. Learning points: TSHomas are mostly diagnosed as macroadenomas in the context of central hyperthyroidism and/or mass-effect central symptomatology. The classical pattern of central hyperthyroidism consists of elevated free thyroid hormones and inadequately normal or slightly increased TSH. If a TSHoma is suspected, the differential diagnosis of thyroid hormone resistance (RTH) must be excluded. Surgical resection is the first-line choice of therapy for TSHomas. In cases of non-operable lesions or postoperative residual tumors, pituitary fractionated stereotactic radiotherapy, radiosurgery, and/or medical treatment with somatostatin analogs can be considered as alternatives. The management of TSHomas must happen in an interdisciplinary way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.